1.
Bianconi E，Piovesan A，Facchin F，Beraudi A，Casadei R，Frabetti F，Vitale L，
Pelleri MC，Tassani S，Piva F，Perez-Amodio S，Strippoli P，Canaider S. An
estimation of the number of cells in the human body. Ann Hum Biol. 40(6):463-71
(2013).
2.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 144(5):646-74
(2011).
3.
Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor
microenvironment. Nat Immunol. 14(10):1014-22 (2013).
4.
Whiteside TL. The tumor microenvironment and its role in promoting tumor growth.
Oncogene. 27(45):5904-12 (2008).
5.
Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor
microenvironment. Cell. 141(1):52-67 (2010).
6.
Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the
tumor microenvironment. Cancer Cell. 21(3):309-22 (2012).
7.
Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on
therapeutic response. Nature. 501(7467):346-54 (2013).
8.
Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis.
83
Nat Med. 19(11):1423-37 (2013).
9.
Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis.
Cell. 141(1):39-51 (2010).
10. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration,
invasion, and metastasis. Cell. 124(2):263-6 (2006).
11. Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ, Stanley ER, Segall JE,
Condeelis JS. Macrophages promote the invasion of breast carcinoma cells via a colonystimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 65(12):5278-83
(2005).
12. Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, Segall JE.
Microglial stimulation of glioblastoma invasion involves epidermal growth factor
receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med.
18:519-27 (2012).
13. Kalluri R, Zeisberg M Fibroblasts in cancer. Nat Rev Cancer. 6(5):392-401 (2006).
14. Marsh T, Pietras K, McAllister SS. Fibroblasts as architects of cancer pathogenesis.
Biochim Biophys Acta. 1832(7):1070-8 (2013).
15. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T,
Jain RK, Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell.
84
94(6):715-25 (1998).
16. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-Associated Fibroblasts Are
Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an
NF-kappaB-Dependent Manner. Cancer Cell. 17(2):135-47 (2010).
17. Fang H, Declerck YA. Targeting the tumor microenvironment: from understanding
pathways to effective clinical trials. Cancer Res. 73(16):4965-77 (2013).
18. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev
Cancer. 12(4):252-64 (2012).
19. Lee RC，Feinbaum RL，Ambros V. The C. elegans heterochronic gene lin-4 encodes
small RNAs with antisense complementarity to lin-14. Cell. 75(5):843-54 (1993).
20. Wightman B，Ha I，Ruvkun G. Posttranscriptional regulation of the heterochronic gene
lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 75(5):855-62
(1993).
21. Ambros V，Chen X. The regulation of genes and genomes by small RNAs.
Development. 134(9):1635-41 (2007).
22. Bartel DP. MicroRNAs: genomics，biogenesis，mechanism，and function. Cell.
116(2):281-97 (2004).
23. Ha M，Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol.
85
15(8):509-24 (2014).
24. Suzuki HI，Miyazono K. Emerging complexity of microRNA generation cascades. J
Biochem. 149(1):15-25 (2011).
25. Denli AM，Tops BB，Plasterk RH，Ketting RF，Hannon GJ. Processing of primary
microRNAs by the Microprocessor complex. Nature. 432(7014):231-5 (2004).
26. Gregory RI，Yan KP，Amuthan G，Chendrimada T，Doratotaj B，Cooch N，
Shiekhattar R. The Microprocessor complex mediates the genesis of microRNAs. Nature.
432(7014):235-40 (2004).
27. Liu J，Carmell MA，Rivas FV，Marsden CG，Thomson JM，Song JJ，Hammond
SM，Joshua-Tor L，Hannon GJ. Argonaute2 is the catalytic engine of mammalian
RNAi. Science. 305(5689):1437-41 (2004).
28. Lewis BP，Burge CB，Bartel DP. Conserved seed pairing，often flanked by
adenosines，indicates that thousands of human genes are microRNA targets. Cell.
120(1):15-20 (2005).
29. Friedman RC，Farh KK，Burge CB，Bartel DP. Most mammalian mRNAs are
conserved targets of microRNAs. Genome Res. 19(1):92-105 (2009).
30. Miranda KC，Huynh T，Tay Y，Ang YS，Tam WL，Thomson AM，Lim B，
Rigoutsos I. A pattern-based method for the identification of MicroRNA binding sites and
86
their corresponding heteroduplexes. Cell. 126(6):1203-17 (2006).
31. Suzuki HI，Miyazono K. Dynamics of microRNA biogenesis: crosstalk between p53
network and microRNA processing pathway. J Mol Med (Berl). 88(11):1085-94 (2010).
32. He L，Thomson JM，Hemann MT，Hernando-Monge E，Mu D，Goodson S，
Powers S，Cordon-Cardo C，Lowe SW，Hannon GJ，Hammond SM. A microRNA
polycistron as a potential human oncogene. Nature. 435(7043):828-33 (2005).
33. Calin GA，Dumitru CD，Shimizu M，Bichi R，Zupo S，Noch E，Aldler H，Rattan
S，Keating M，Rai K，Rassenti L，Kipps T，Negrini M，Bullrich F，Croce CM.
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at
13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 99(24):15524-9
(2002).
34. Suzuki HI，Yamagata K，Sugimoto K，Iwamoto T，Kato S，Miyazono K.
Modulation of microRNA processing by p53. Nature. 460(7254):529-33 (2009).
35. Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA. microRNA Therapeutics
in Cancer - An Emerging Concept. EBioMedicine. 12:34-42 (2016).
36. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann
G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell
JT. Transactivation of miR-34a by p53 broadly influences gene expression and promotes
87
apoptosis. Mol Cell. 26(5):745-52 (2007).
37. Tsunoda T, Takashima Y, Yoshida Y, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T,
Koyanagi M, Kuroki M, Sasazuki T, Shirasawa S. Oncogenic KRAS regulates miR-200c
and miR-221/222 in a 3D-specific manner in colorectal cancer cells. Anticancer Res.
31(7):2453-9 (2011).
38. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal
transition and cancer cell migration by direct targeting of E-cadherin transcriptional
repressors ZEB1 and ZEB2. J Biol Chem. 283(22):14910-4 (2008).
39. Soda M，Choi YL，Enomoto M，Takada S，Yamashita Y，Ishikawa S，Fujiwara S，
Watanabe H，Kurashina K，Hatanaka H，Bando M，Ohno S，Ishikawa Y，Aburatani
H，Niki T，Sohara Y，Sugiyama Y，Mano H. Identification of the transforming
EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448(7153):561-6 (2007).
40. Chiarle R，Voena C，Ambrogio C，Piva R，Inghirami G. The anaplastic lymphoma
kinase in the pathogenesis of cancer. Nat Rev Cancer. 8(1):11-23 (2008).
41. Zhao Z，Verma V，Zhang M. Anaplastic lymphoma kinase: Role in cancer and therapy
perspective. Cancer Biol Ther. 16(12):1691-701 (2015).
42. Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB,
Sanchez NS, Zeng J, Shufean MA, Shaw KR, Mendelsohn J, Mills GB, Meric-Bernstam
88
F, Simon GR. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol
Case Stud. 3(1):a001115 (2017).
43. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B,
Yamamoto T. Molecular characterization of ALK, a receptor tyrosine kinase expressed
specifically in the nervous system. Oncogene. 14(4):439-49 (1997).
44. Swerdlow SH，Campo E，Harris NL，Jaffe ES，Pileri SA，Stein H，Thiele J. WHO
Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth Edition，
Lyon，IARC Press; 2008.
45. Swerdlow SH，Campo E，Pileri SA，Harris NL，Stein H，Siebert R，Advani R，
Ghielmini M，Salles GA，Zelenetz AD，Jaffe ES. The 2016 revision of the World
Health Organization classification of lymphoid neoplasms. Blood. 127(20):2375-90
(2016).
46. Morris SW，Kirstein MN，Valentine MB，Dittmer KG，Shapiro DN，Saltman DL，
Look AT. Fusion of a kinase gene，ALK，to a nucleolar protein gene，NPM，in nonHodgkin's lymphoma. Science. 263(5151):1281-4 (1994).
47. Hallberg B，Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in
human cancer biology. Nat Rev Cancer. 13(10):685-700 (2013).
48. Ambrogio C，Martinengo C，Voena C，Tondat F，Riera L，di Celle PF，Inghirami
89
G，Chiarle R. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by
transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res.
69(22):8611-9 (2009).
49. Pearson JD，Lee JK，Bacani JT，Lai R，Ingham RJ. NPM-ALK and the JunB
transcription factor regulate the expression of cytotoxic molecules in ALK-positive，
anaplastic large cell lymphoma. Int J Clin Exp Pathol. 4(2):124-33 (2011).
50. Ambrogio C，Voena C，Manazza AD，Martinengo C，Costa C，Kirchhausen T，
Hirsch E，Inghirami G，Chiarle R. The anaplastic lymphoma kinase controls cell shape
and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res.
68(21):8899-907 (2008).
51. Lawrie CH，Saunders NJ，Soneji S，Palazzo S，Dunlop HM，Cooper CD，Brown
PJ，Troussard X，Mossafa H，Enver T，Pezzella F，Boultwood J，Wainscoat JS，
Hatton CS. MicroRNA expression in lymphocyte development and malignancy.
Leukemia. 22(7):1440-6 (2008).
52. Merkel O，Hamacher F，Laimer D，Sifft E，Trajanoski Z，Scheideler M，Egger
G，Hassler MR，Thallinger C，Schmatz A，Turner SD，Greil R，Kenner L.
Identification of differential and functionally active miRNAs in both anaplastic
lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci
90
U S A. 107(37):16228-33 (2010).
53. Haraguchi T，Ozaki Y，Iba H. Vectors expressing efficient RNA decoys achieve the
long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids
Res. 37(6):e43 (2009).
54. Piva R，Pellegrino E，Mattioli M，Agnelli L，Lombardi L，Boccalatte F，Costa G，
Ruggeri BA，Cheng M，Chiarle R，Palestro G，Neri A，Inghirami G. Functional
validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1
as critical target genes. J Clin Invest. 116(12):3171-82 (2006).
55. Anastasov N，Klier M，Koch I，Angermeier D，Höfler H，Fend F，QuintanillaMartinez L. Efficient shRNA delivery into B and T lymphoma cells using lentiviral
vector-mediated transfer. J Hematop. 2(1):9-19 (2009).
56. Bromberg JF，Wrzeszczynska MH，Devgan G，Zhao Y，Pestell RG，Albanese C，
Darnell JE Jr. Stat3 as an oncogene. Cell. 98(3):295-303 (1999).
57. Iqbal J，Weisenburger DD，Greiner TC，Vose JM，McKeithan T，Kucuk C，Geng
H，Deffenbacher K，Smith L，Dybkaer K，Nakamura S，Seto M，Delabie J，
Berger F，Loong F，Au WY，Ko YH，Sng I，Armitage JO，Chan WC; International
Peripheral T-Cell Lymphoma Project. Molecular signatures to improve diagnosis in
peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.
91
Blood. 115(5):1026-36 (2010).
58. Subramanian A，Tamayo P，Mootha VK，Mukherjee S，Ebert BL，Gillette MA，
Paulovich A，Pomeroy SL，Golub TR，Lander ES，Mesirov JP. Gene set enrichment
analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
Proc Natl Acad Sci U S A. 102(43):15545-50 (2005).
59. Marzec M, Kasprzycka M, Ptasznik A, Wlodarski P, Zhang Q, Odum N, Wasik MA.
Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and
suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest.
85(12):1544-54 (2005).
60. Saito T，Saetrom P. MicroRNAs--targeting and target prediction. N Biotechnol.
27(3):243-9 (2010).
61. Nagel R，le Sage C，Diosdado B，van der Waal M，Oude Vrielink JA，Bolijn A，
Meijer GA，Agami R. Regulation of the adenomatous polyposis coli gene by the miR135 family in colorectal cancer. Cancer Res. 68(14):5795-802 (2008).
62. Kuiper RP，Schoenmakers EF，van Reijmersdal SV，Hehir-Kwa JY，van Kessel
AG，van Leeuwen FN，Hoogerbrugge PM. High-resolution genomic profiling of
childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in
lymphocyte differentiation and cell cycle progression. Leukemia. 21(6):1258-66 (2007).
92
63. Gu TL，Tothova Z，Scheijen B，Griffin JD，Gilliland DG，Sternberg DW. NPMALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative
signaling through modulation of FOXO3a. Blood. 103(12):4622-9 (2004).
64. Greer EL，Brunet A. FOXO transcription factors at the interface between longevity and
tumor suppression. Oncogene. 24(50):7410-25 (2005).
65. Harrington LE，Hatton RD，Mangan PR，Turner H，Murphy TL，Murphy KM，
Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct
from the T helper type 1 and 2 lineages. Nat Immunol. 6(11):1123-32 (2005).
66. Lazarevic V，Chen X，Shim JH，Hwang ES，Jang E，Bolm AN，Oukka M，
Kuchroo VK，Glimcher LH. T-bet represses TH17 differentiation by preventing Runx1mediated activation of the gene encoding RORγt. Nat Immunol. 12(1):96-104 (2011).
67. van Hamburg JP，Mus AM，de Bruijn MJ，de Vogel L，Boon L，Cornelissen F，
Asmawidjaja P，Hendriks RW，Lubberts E. GATA-3 protects against severe joint
inflammation and bone erosion and reduces differentiation of Th17 cells during
experimental arthritis. Arthritis Rheum. 60(3):750-9 (2009).
68. Zhou M，Ouyang W. The function role of GATA-3 in Th1 and Th2 differentiation.
Immunol Res. 28(1):25-37 (2003).
69. McGeachy MJ，Cua DJ. Th17 cell differentiation: the long and winding road. Immunity.
93
28(4):445-53 (2008).
70. Okamoto K, Iwai Y, Oh-Hora M, Yamamoto M, Morio T, Aoki K, Ohya K, Jetten AM,
Akira S, Muta T, Takayanagi H. IB regulates TH17 development by cooperating with
ROR nuclear receptors. Nature. 464(7293):1381-5 (2010).
71. Yang XO，Chang SH，Park H，Nurieva R，Shah B，Acero L，Wang YH，Schluns
KS，Broaddus RR，Zhu Z，Dong C. Regulation of inflammatory responses by IL-17F.
J Exp Med. 205(5):1063-75 (2008).
72. Ji Y，Zhang W. Th17 cells: positive or negative role in tumor? Cancer Immunol
Immunother. 59(7):979-87 (2010).
73. Zou W，Restifo NP. TH17 cells in tumour immunity and immunotherapy. Nat Rev
Immunol. 10(4):248-56 (2010).
74. Numasaki M，Fukushi J，Ono M，Narula SK，Zavodny PJ，Kudo T，Robbins PD，
Tahara H，Lotze MT. Interleukin-17 promotes angiogenesis and tumor growth. Blood.
101(7):2620-7 (2003).
75. Numasaki M，Watanabe M，Suzuki T，Takahashi H，Nakamura A，McAllister F，
Hishinuma T，Goto J，Lotze MT，Kolls JK，Sasaki H. IL-17 enhances the net
angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID
mice through promoting CXCR-2-dependent angiogenesis. J Immunol. 175(9):6177-89
94
(2005).
76. Lin CW，Chang YL，Chang YC，Lin JC，Chen CC，Pan SH，Wu CT，Chen HY，
Yang SC，Hong TM，Yang PC. MicroRNA-135b promotes lung cancer metastasis by
regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun. 4:1877
(2013).
77. Horie R，Watanabe M，Ishida T，Koiwa T，Aizawa S，Itoh K，Higashihara M，
Kadin ME，Watanabe T. The NPM-ALK oncoprotein abrogates CD30 signaling and
constitutive NF-B activation in anaplastic large cell lymphoma. Cancer Cell. 5(4):35364 (2004).
78. Lin CH，Jackson AL，Guo J，Linsley PS，Eisenman RN. Myc-regulated microRNAs
attenuate embryonic stem cell differentiation. EMBO J. 28(20):3157-70 (2009).
79. Tong AW，Fulgham P，Jay C，Chen P，Khalil I，Liu S，Senzer N，Eklund AC，
Han J，Nemunaitis J. MicroRNA profile analysis of human prostate cancers. Cancer
Gene Ther. 16(3):206-16 (2009).
80. Bowman T，Garcia R，Turkson J，Jove R. STATs in oncogenesis. Oncogene.
19(21):2474-88 (2000).
81. Ara T，Nakata R，Sheard MA，Shimada H，Buettner R，Groshen SG，Ji L，Yu
H，Jove R，Seeger RC，DeClerck YA. Critical role of STAT3 in IL-6-mediated drug
95
resistance in human neuroblastoma. Cancer Res. 73(13):3852-64 (2013).
82. Tomiyama A，Uekita T，Kamata R，Sasaki K，Takita J，Ohira M，Nakagawara A，
Kitanaka C，Mori K，Yamaguchi H，Sakai R. Flotillin-1 regulates oncogenic signaling
in neuroblastoma cells by regulating ALK membrane association. Cancer Res.
74(14):3790-801 (2014).
83. Koivunen JP1，Mermel C，Zejnullahu K，Murphy C，Lifshits E，Holmes AJ，Choi
HG，Kim J，Chiang D，Thomas R，Lee J，Richards WG，Sugarbaker DJ，Ducko
C，Lindeman N，Marcoux JP，Engelman JA，Gray NS，Lee C，Meyerson M，
Jänne PA. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung
cancer. Clin Cancer Res. 14(13):4275-83 (2008).
84. Yuki D，Lin YM，Fujii Y，Nakamura Y，Furukawa Y. Isolation of LEM domaincontaining 1，a novel testis-specific gene expressed in colorectal cancers. Oncol Rep.
12(2):275-80 (2004).
85. Jones AM，Douglas EJ，Halford SE，Fiegler H，Gorman PA，Roylance RR，Carter
NP，Tomlinson IP. Array-CGH analysis of microsatellite-stable，near-diploid bowel
cancers and comparison with other types of colorectal carcinoma. Oncogene. 24(1):11829 (2005).
86. Douglas EJ，Fiegler H，Rowan A，Halford S，Bicknell DC，Bodmer W，Tomlinson
96
IP，Carter NP. Array comparative genomic hybridization analysis of colorectal cancer
cell lines and primary carcinomas. Cancer Res. 64(14):4817-25 (2004).
87. Sasahira T，Kurihara M，Nakashima C，Kirita T，Kuniyasu H. LEM domain
containing 1 promotes oral squamous cell carcinoma invasion and endothelial
transmigration. Br J Cancer. 115(1):52-8 (2016).
88. Liu C，Iqbal J，Teruya-Feldstein J，Shen Y，Dabrowska MJ，Dybkaer K，Lim
MS，Piva R，Barreca A，Pellegrino E，Spaccarotella E，Lachel CM，Kucuk C，
Jiang CS，Hu X，Bhagavathi S，Greiner TC，Weisenburger DD，Aoun P，Perkins
SL，McKeithan TW，Inghirami G，Chan WC. MicroRNA expression profiling
identifies molecular signatures associated with anaplastic large cell lymphoma. Blood.
122(12):2083-92 (2013).
89. Spaccarotella E，Pellegrino E，Ferracin M，Ferreri C，Cuccuru G，Liu C，Iqbal J，
Cantarella D，Taulli R，Provero P，Di Cunto F，Medico E，Negrini M，Chan WC，
Inghirami G，Piva R. STAT3-mediated activation of microRNA cluster 17~92 promotes
proliferation and survival of ALK-positive anaplastic large cell lymphoma.
Haematologica. 99(1):116-24 (2014).
90. Steinhilber J，Bonin M，Walter M，Fend F，Bonzheim I，Quintanilla-Martinez L.
Next-generation sequencing identifies deregulation of microRNAs involved in both
97
innate and adaptive immune response in ALK+ ALCL. PLoS One. 10(2):e0117780
(2015).
91. Dejean E，Renalier MH，Foisseau M，Agirre X，Joseph N，de Paiva GR，Al Saati
T，Soulier J，Desjobert C，Lamant L，Prósper F，Felsher DW，Cavaillé J，Prats
H，Delsol G，Giuriato S，Meggetto F. Hypoxia-microRNA-16 downregulation induces
VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell
lymphomas. Leukemia. 25(12):1882-90 (2011).
92. Zhu H，Vishwamitra D，Curry CV，Manshouri R，Diao L，Khan A，Amin HM.
NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent
mechanism. J Pathol. 230(1):82-94 (2013).
93. Desjobert C，Renalier MH，Bergalet J，Dejean E，Joseph N，Kruczynski A，Soulier
J，Espinos E，Meggetto F，Cavaillé J，Delsol G，Lamant L. MiR-29a downregulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis
blockade through MCL-1 overexpression. Blood. 117(24):6627-37 (2011).
94. Hoareau-Aveilla C，Valentin T，Daugrois C，Quelen C，Mitou G，Quentin S，Jia
J，Spicuglia S，Ferrier P，Ceccon M，Giuriato S，Gambacorti-Passerini C，Brousset
P，Lamant L，Meggetto F. Reversal of microRNA-150 silencing disadvantages
crizotinib-resistant NPM-ALK+ cell growth. J Clin Invest. 125(9):3505-18 (2015).
98
95. Zhang Q，Wang H，Kantekure K，Paterson JC，Liu X，Schaffer A，Paulos C，
Milone MC，Odum N，Turner S，Marafioti T，Wasik MA. Oncogenic tyrosine kinase
NPM-ALK induces expression of the growth-promoting receptor ICOS. Blood.
118(11):3062-71 (2011).
96. Vishwamitra D，Li Y，Wilson D，Manshouri R，Curry CV，Shi B，Tang XM，
Sheehan AM，Wistuba II，Shi P，Amin HM. MicroRNA 96 is a post-transcriptional
suppressor of anaplastic lymphoma kinase expression. Am J Pathol. 180(5):1772-80
(2012).
97. Suzuki HI，Mihira H，Watabe T，Sugimoto K，Miyazono K. Widespread inference of
weighted microRNA-mediated gene regulation in cancer transcriptome analysis. Nucleic
Acids Res. 41(5):e62 (2013).
98. Suzuki HI，Matsuyama H，Noguchi M，Yao T，Komatsu N，Mano H，Sugimoto
K，Miyazono K. Computational dissection of distinct microRNA activity signatures
associated with peripheral T cell lymphoma subtypes. Leukemia. 27(10):2107-11 (2013).
99. Savan R，McFarland AP，Reynolds DA，Feigenbaum L，Ramakrishnan K，Karwan
M，Shirota H，Klinman DM，Dunleavy K，Pittaluga S，Anderson SK，Donnelly
RP，Wilson WH，Young HA. A novel role for IL-22R1 as a driver of inflammation.
Blood. 117(2):575-84 (2011).
99
100.Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 9(1):15-27 (2009).
101.Tripodo C，Gri G，Piccaluga PP，Frossi B，Guarnotta C，Piconese S，Franco G，
Vetri V，Pucillo CE，Florena AM，Colombo MP，Pileri SA. Mast cells and Th17 cells
contribute to the lymphoma-associated pro-inflammatory microenvironment of
angioimmunoblastic T-cell lymphoma. Am J Pathol. 177(2):792-802 (2010).
102.Mann KP，Hall B，Kamino H，Borowitz MJ，Ratech H. Neutrophil-rich，Ki-1positive anaplastic large-cell malignant lymphoma. Am J Surg Pathol. 19(4):407-16
(1995).
103. Tamiolakis D，Georgiou G，Prassopoulos P，Simopoulos C，Venizelos J，
Papadopoulos N. Neutrophil-rich anaplastic large cell lymphoma (NR-ALCL) mimicking
lymphadenitis: a study by fine-needle aspiration biopsy. Leuk Lymphoma. 45(6):1309-10
(2004).
104. Engsig FN，Møller MB，Hasselbalch HK，Mahdi B，Obel N. Extreme neutrophil
granulocytosis in a patient with anaplastic large cell lymphoma of T-cell lineage. APMIS.
115(6):778-83 (2007).
105. Du C，Liu C，Kang J，Zhao G，Ye Z，Huang S，Li Z，Wu Z，Pei G. MicroRNA
miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of
multiple sclerosis. Nat Immunol. 10(12):1252-9 (2009).
100
106. O'Connell RM，Kahn D，Gibson WS，Round JL，Scholz RL，Chaudhuri AA，
Kahn ME，Rao DS，Baltimore D. MicroRNA-155 promotes autoimmune inflammation
by enhancing inflammatory T cell development. Immunity. 33(4):607-19 (2010).
107. Rodriguez A，Vigorito E，Clare S，Warren MV，Couttet P，Soond DR，van
Dongen S，Grocock RJ，Das PP，Miska EA，Vetrie D，Okkenhaug K，Enright AJ，
Dougan G，Turner M，Bradley A. Requirement of bic/microRNA-155 for normal
immune function. Science. 316(5824):608-11 (2007).
108. Luo Y，Deng Y，Tao Z，Chen S，Xiao B，Ren J，Chen Z，Han J，Kong Y，Xu
Y，Deng M. Regulatory effect of microRNA-135a on the Th1/Th2 imbalance in a
murine model of allergic rhinitis. Exp Ther Med. 8(4):1105-1110 (2014).
109. Suzuki HI, Katsura A, Matsuyama H, Miyazono K. MicroRNA regulons in tumor
microenvironment. Oncogene. 34(24):3085-94 (2015).
110. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt
F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA.
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis.
Nat Cell Biol. 12(3):247-56 (2010).
111. Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. GATA3 suppresses metastasis
and modulates the tumour microenvironment by regulating microRNA-29b expression.
101
Nat Cell Biol. 15(2):201-13 (2013).
112. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, Lengyel E.
MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian
cancer. Cancer Discov. 2(12):1100-8 (2012).
113. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H,
Srinivasan R, Trimboli AJ, Martin CK, Li F, Yu L, Fernandez SA, Pécot T, Rosol TJ,
Cory S, Hallett M, Park M, Piper MG, Marsh CB, Yee LD, Jimenez RE, Nuovo G,
Lawler SE, Chiocca EA, Leone G, Ostrowski MC. Reprogramming of the tumour
microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol. 14(2):159-67
(2011).
114. Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Saccà M, Memeo L,
Colarossi C, Francescangeli F, Biffoni M, Collura D, Giacobbe A, D'Urso L, Falchi M,
Venneri MA, Muto G, De Maria R, Bonci D. Control of tumor and microenvironment
cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene. 30(41):4231-42 (2011).
115. Beg MS，Brenner AJ，Sachdev J，Borad M，Kang YK，Stoudemire J，Smith S6，
Bader AG，Kim S，Hong DS. Phase I study of MRX34，a liposomal miR-34a mimic，
administered twice weekly in patients with advanced solid tumors. Invest New Drugs.
35(2):180-188 (2017).
102
116. Kreth S，Hübner M，Hinske LC. MicroRNAs as Clinical Biomarkers and Therapeutic
Tools in Perioperative Medicine. Anesth Analg. 126(2):670-681 (2018).
117. Due H，Svendsen P，Bødker JS，Schmitz A，Bøgsted M，Johnsen HE，El-Galaly
TC，Roug AS，Dybkær K. miR-155 as a Biomarker in B-Cell Malignancies. Biomed
Res Int. 2016:9513037 (2016).
118. Zhang Y，Roccaro AM，Rombaoa C，Flores L，Obad S，Fernandes SM，Sacco
A，Liu Y，Ngo H，Quang P，Azab AK，Azab F，Maiso P，Reagan M，Brown
JR，Thai TH，Kauppinen S，Ghobrial IM. LNA-mediated anti-miR-155 silencing in
low-grade B-cell lymphomas. Blood. 120(8): 1678-86 (2012).
119. Lieberman J, Sharp PA. Harnessing RNA interference for therapy: the silent treatment.
JAMA. 313(12):1207-8 (2015).
120. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der
Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA,
Hodges MR. Treatment of HCV infection by targeting microRNA. N Engl J Med.
368(18):1685-94 (2013).
103
...
論文の公開元へ
